Lateral differences in Ki‑67 in breast cancer

Dmitrenko,Alexey Petrovich

doi:10.3892/mco.2016.845

Lateral differences in Ki‑67 in breast cancer

Authors:
- Alexey Petrovich Dmitrenko
View Affiliations

Affiliations: State Budgetary Institution of Public Health Services of The Rostov Region, Oncologic Dispensary, Rostov‑on‑Don 344006, Russia
Published online on: April 4, 2016 https://doi.org/10.3892/mco.2016.845
Pages: 1041-1044

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Morphological features of right‑ and left‑sided breast cancer (BC) have been rarely studied. Ki‑67 is an independent predictive marker for a local relapse, and for overall and disease‑free survival. In previous literature, lateral differences in Ki‑67 in BC have not been reported. Using immunohistochemical analysis, the biopsy material of 500 patients was investigated. Four BC parameters were investigated: The expression levels of the estrogen receptor (ER), progesterone receptor (PR), Ki‑67 and Her‑2‑neu. A comparative analysis of Ki‑67 in groups with right‑ and left‑sided BC was performed. Lateral differences in Ki‑67 in three age groups, ≤49, 50‑59 and ≥60 years, were assessed. A higher expression of Ki‑67 corresponded with right‑sided BC (r=‑0.08; P=0.046). Correlation of Ki‑67 with the age of the patient was characteristic only for right‑sided BC (r=‑0.28; P<0.001). The comparative analysis revealed that tumors from patients with right‑sided BC aged ≥60 years exhibited a lower Ki‑67 index compared with tumors from patients aged ≤49 (P=0.003) and 50‑59 years (P=0.000013). In left‑sided BC, the Ki‑67 in the different age intervals revealed no significant difference. On performing an assessment of lateral differences for the different age intervals, it was established that the Ki‑67 index of right‑sided BC was significantly higher compared with the left‑sided BC in two of the age groups, ≤49 (P=0.038) and 50‑59 years (P=0.047). In the ≥60 years group, lateral differences in Ki‑67 were not revealed (P=0.4). The analysis of lateral differences in Ki‑67 in tumors of various receptor profiles revealed significant differences in Ki‑67 of the right‑ and left‑sided BC under ER+ PR‑ (P=0.007) and ER‑ PR‑ (P=0.016) conditions. The reasons behind lateral and age differences of Ki-67 are discussed.

View Figures

View References

1	Fatima N, Zaman MU, Maqbool A, Khan SH and Riaz N: Lower incidence but more aggressive behavior of right sided breast cancer in pakistani women: does right deserve more respect? Asian Pac J Cancer Prev. 14:43–45. 2013. View Article : Google Scholar : PubMed/NCBI
2	Borisenkov MF and Bazhenov SM: Survival in human breast cancer: effects of tumor laterality and the time of year of surgery. Human Physiology. 27:631–634. 2001.(In Russian). View Article : Google Scholar
3	Bao J, Yu K-D, Jiang Y-Z, Shao Z-M and Di G-H: The effect of laterality and primary tumor site on cancer-specific mortality in breast cancer: a SEER population-based study. PLoS ONE. 9:e948152014. View Article : Google Scholar : PubMed/NCBI
4	Aareleĭd TP and Khint EK: Prevalence of tumors in the left breast. Vopr Onkol. 33:37–42. 1987.(In Russian).
5	Tulinius H, Sigvaldason H and Olafsdóttir G: Left and right sided breast cancer. Pathol Res Pract. 186:92–94. 1990. View Article : Google Scholar : PubMed/NCBI
6	Weiss HA, Devesa SS and Brinton LA: Laterality of breast cancer in the United States. Cancer Causes Control. 7:539–543. 1996. View Article : Google Scholar : PubMed/NCBI
7	Perkins CI, Hotes J, Kohler BA and Howe HL: Association between breast cancer laterality and tumor location, United States, 1994–1998. Cancer Causes Control. 15:637–645. 2004. View Article : Google Scholar : PubMed/NCBI
8	Melnik Y, Slater PE, Steinitz R and Davies AM: Breast cancer in Israel: Laterality and survival. J Cancer Res Clin Oncol. 95:291–293. 1979. View Article : Google Scholar : PubMed/NCBI
9	Erendeeva LE, Zav'yalova MB, Slonimskaya EM and Perelmuter VM: Influence of functional asymmetry on the forecast of a breast cancer. Byul Sib Med. 1:36–39. 2002.(In Russian).
10	Hartveit F, Tangen M and Hartveit E: Side and survival in breast cancer. Oncology. 41:149–154. 1984. View Article : Google Scholar : PubMed/NCBI
11	Nouh MA, Ismail H, El-Din NH and El-Bolkainy MN: Lymph node metastasis in breast carcinoma: Clinicopathologic correlations in 3747 patients. J Egypt Natl Canc Inst. 16:50–56. 2004.PubMed/NCBI
12	Mandard AM, Denoux Y, Herlin P, Duigou F, van De Vijver MJ, Clahsen PC, van Den Broek L, Sahmoud TM, Henry-Amar M and van De Velde CJ: Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial: Multivariate analysis with Ki-67 index, mitotic count and microvessel density. Cancer. 89:1748–1757. 2000. View Article : Google Scholar : PubMed/NCBI
13	Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M and Gusterson BA: International Breast Cancer Study Group: Ki-67 expression in breast carcinoma: Its association with grading systems, clinical parameters, and other prognostic factors-a surrogate marker? Cancer. 97:1321–1331. 2003. View Article : Google Scholar : PubMed/NCBI
14	Ponzone R, Montemurro F, Maggiorotto F, Robba C, Gregori D, Jacomuzzi ME, Kubatzki F, Marenco D, Dominguez A, Biglia N and Sismondi P: Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer. Ann Oncol. 17:1631–1636. 2006. View Article : Google Scholar : PubMed/NCBI
15	Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price KN, Golouh R, Perin T, Brown RW, et al: Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst. 100:207–212. 2008. View Article : Google Scholar : PubMed/NCBI
16	Penault-Llorca F, Abrial C, Raoelfils I, Cholletac P, Cayrea A, Mouret-Reynier M, Thivat E, Mishellany F, Gimbergues P and Durando X: Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist. 13:1235–1245. 2008. View Article : Google Scholar : PubMed/NCBI
17	Li L, Mu K, Zhou G, Lan L, Auer G and Zetterberg A: Genomic instability and proliferative activity as risk factors for distant metastases in breast cancer. Br J Cancer. 99:513–519. 2008. View Article : Google Scholar : PubMed/NCBI
18	Darb-Esfahani S, Loibl S, Müller BM, Roller M, Denkert C, Komor M, Schlüns K, Blohmer JU, Budczies J, Gerber B, et al: Identification of biology-based breast cancer types with distinct predictive and prognostic features: Role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res. 11:R692009. View Article : Google Scholar : PubMed/NCBI
19	Sharma S, Hiran KR, Pavithran K and Vijaykumar DK: A pilot study to assess the feasibility of evaluation of markers of response to chemotherapy at one day & 21 days after first cycle of chemotherapy in carcinoma of breast: A prospective non-randomized observational study. World J Surg Oncol. 7:352009. View Article : Google Scholar : PubMed/NCBI
20	Dowsett M, A'Hern R, Salter J, Zabaglo L and Smith IE: Who would have thought a single Ki67 measurement would predict long-term outcome? Breast Cancer Res. 11(Suppl 3): S152009. View Article : Google Scholar : PubMed/NCBI
21	Rodger A: Who would have thought it! Influence on outcome of radiotherapy, Ki67 and stroma. Introduction to Session 5. Breast Cancer Res. 11(Suppl 3): S132009. View Article : Google Scholar : PubMed/NCBI
22	Yerushalmi R, Woods R, Ravdin PM, Hayes MM and Gelmon KA: Ki67 in breast cancer: Prognostic and predictive potential. Lancet Oncol. 11:174–183. 2010. View Article : Google Scholar : PubMed/NCBI
23	Shokouh TZ, Ezatollah A and Barand P: Interrelationships between Ki67, HER2/neu, p53, ER and PR status and their associations with tumor grade and lymph node involvement in breast carcinoma subtypes: Retrospective-observational analytical study. Medicine (Baltimore). 94:e13592015. View Article : Google Scholar : PubMed/NCBI
24	Dabbs D: Diagnostic Immunohistochemistry (2nd). Philadelphia: Elsevier. 699–746. 2006. View Article : Google Scholar
25	Jung P, Baumgärtner U, Stoeter P and Treede R-D: Structural and Functional Asymmetry in the Human Parietal Opercular Cortex. Journal of Neurophysiology. 101:3246–3257. 2009. View Article : Google Scholar : PubMed/NCBI
26	Cabeza R: Hemispheric asymmetry reduction in older adults: the HAROLD model. Psychol Aging. 17:85–100. 2002. View Article : Google Scholar : PubMed/NCBI
27	Dolcos F, Rice HJ and Cabeza R: Hemispheric asymmetry and aging: right hemisphere decline or asymmetry reduction. Neurosci Biobehav Rev. 26:819–825. 2002. View Article : Google Scholar : PubMed/NCBI
28	Poroshenko AB: About the nature of deficiency of anticancer resistance of an organism. Sbornik nauchnykh trudov RNIOI. Sposoby i mekhanizmy povysheniya protivoopukholevoi zashchity v onkologii (Moskva). 211–257. 1993.(In Russian).